Patents Issued in January 4, 2024
  • CARDIAC STEM CELLS FOR CARDIAC REPAIR
    Publication number: 20240000851
    Abstract: Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 4, 2024
    Inventor: Sunjay KAUSHAL
  • THERAPEUTIC USE OF CELL-FREE FAT EXTRACT FOR OSTEOPOROSIS
    Publication number: 20240000852
    Abstract: A cell-free fat extract is used for the preparation of a composition or a formulation. The composition or the formulation is effective in (i) preventing and/or treating osteoporosis; (ii) increasing bone volume fraction; (iii) increasing trabecular number; (iv) increasing trabecular connectivity density; (v) increasing bone mineral density; (vi) increasing trabecular thickness; and/or (vii) reducing trabecular separation.
    Type: Application
    Filed: November 30, 2021
    Publication date: January 4, 2024
    Inventors: Zhifeng YU, Mingming XU, Wenjie ZHANG
  • LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE PRODUCTION PROMOTING AGENT
    Publication number: 20240000853
    Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 4, 2024
    Applicants: HYOGO COLLEGE OF MEDICINE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro MATSUYAMA, Takayuki NAKAGOMI, Yu FUKUDA
  • METHOD FOR PREPARING HIGH-CONCENTRATION STEM CELL EXOSOMES WITH ENHANCED ANTI-INFLAMMATORY AND REGENERATIVE FUNCTIONS USING LIPOPOLYSACCHARIDE AND LIPOTEICHOIC ACID
    Publication number: 20240000854
    Abstract: A method for producing high-concentration stem cell exosomes with enhanced anti-inflammatory function using Lipopolysaccharide (LPS) and/or Lipoteichoic Acid (LTA), as well as anti-inflammatory and/or regenerative compositions that can be produced by the aforementioned method are disclosed. The production method for the anti-inflammatory composition includes a first step of treating stem cells during cultivation with one or more selected from a group consisting of Lipopolysaccharide (LPS) and Lipoteichoic Acid (LTA), and optionally, a second step of separating stem cells, their culture medium, and/or their exosomes obtained as a result of the first step.
    Type: Application
    Filed: December 6, 2021
    Publication date: January 4, 2024
    Applicant: PRIMORIS THERAPEUTICS Co., Ltd.
    Inventors: Jae-yong LEE, Hee-jin AHN, Yea-in LEE, Dong-yeol LEE, Kyu-heum NA
  • SPECIFIC PATHOGEN FREE FEED COMPOSITION
    Publication number: 20240000855
    Abstract: The presently claimed invention is directed to a feed composition comprising at least one living worm, wherein the worm is free of pathogens selected from the group consisting of species of Salmonella, species of Campylobacter, Histomonas meleagridis and any combination of two or more of the aforementioned.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 4, 2024
    Inventors: Arnulf TROESCHER, Simon CHAMP, Jörg RIESMEIER
  • STABLE COMPOSITION COMPRISING A HONEY AND A CANNABINOID
    Publication number: 20240000856
    Abstract: Disclosed are compositions comprising a honey, a cannabinoid, and an emulsifier, and compositions comprising methylglyoxal, a cannabinoid and an emulsifier. The emulsifier is preferably cyclodextrin. The composition is stabilised such that the rate of degradation of the active components in honey, including methylglyoxal and dihydroxyacetone, is reduced. The composition is also physically stabilised such that the rate of separation of the cannabinoid is reduced and the homogeneity of the composition is maintained over time.
    Type: Application
    Filed: November 30, 2021
    Publication date: January 4, 2024
    Inventors: Mark James Dye, William Douglas, Owen John Catchpole, Teresa Moreno Rueda, Stephen John Tallon
  • BACTERIA FOR THE PREVENTION AND TREATMENT OF SMOKE-INDUCED LUNG DAMAGE
    Publication number: 20240000857
    Abstract: A method of treating or preventing a disease associated with smoke residue in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one agent which increases the amount of a bacterium which is capable of breaking down the smoke residue in the subject. Methods of alleviating the symptoms caused by withdrawal from the use of nicotine are also disclosed.
    Type: Application
    Filed: March 31, 2021
    Publication date: January 4, 2024
    Applicant: Biomuse Ltd.
    Inventors: Eugene ROSENBERG, Ilana ZILBER-ROSENBERG, Ophir LEVY
  • HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
    Publication number: 20240000858
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: December 20, 2022
    Publication date: January 4, 2024
    Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • DESIGNED BACTERIAL COMPOSITIONS FOR TREATING GRAFT-VERSUS-HOST-DISEASE
    Publication number: 20240000859
    Abstract: Provided herein are bacterial compositions that are useful for treating and preventing complications and side effects associated with a disease or disorder, such as those associated with immune suppression, including infections and/or GvHD, for example, in HSCT subjects. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 4, 2024
    Applicant: Seres Therapeutics, Inc.
    Inventors: Matthew R. HENN, Edward J. O'BRIEN, Ambar PIÑA, Marin VULIC, Christopher B. FORD, Asuncion MARTINEZ, Divya BALASUBRAMANIAN, Elizabeth HALVORSEN, Karen KIESER, Mahmoud SALEH, Mary-Jane LOMBARDO, Sumon DATTA, Madhumitha NANDAKUMAR, Priyanka NARENDAR, Kankana BARDHAN
  • METHODS FOR TREATING AUTISM SPECTRUM DISORDER
    Publication number: 20240000860
    Abstract: Methods and compositions are provided herein for treating autism spectrum disorder in a subject, using one or more metabolites such as glutamate, malate, ursodeoxycholate, 5-dodecenoate, N-acetyl-L-glutamate, citrate, glycodeoxycholate, and carboxyethyl aminobutyric acid (CEGABA) and/or using one or more bacterial species such as bacterial species from the Streptococcaceae, Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, Butyricicoccaceae, and/or Pasteurellaceae families; from the Streptococcus, Blautia, Haemophilus, Faecalibacterium, Bacteroides, Roseburia, Fusicatenibacter, Lachnospira, and/or Agathobaculum genera, or Blautia wexlerae, Bacteroides vulgatus, Bacteroides ovatus, Roseburia inulinivorans, Roseburia intestinalis, Fusicatenibacter saccharivorans, and/or Agathobaculum butyriciproducens.
    Type: Application
    Filed: April 18, 2023
    Publication date: January 4, 2024
    Inventors: Maude M. David, Christine Tataru, Alexandra Rose Phillips, Shoko Kawana, Xiaochen Yin, Marie Peras, Todd Z. DeSantis, Brianna Chrisman, Dennis Wall
  • THERAPEUTIC BACTERIAL COMPOSITION
    Publication number: 20240000861
    Abstract: The disclosure relates to therapeutic compositions comprising isolated bacteria useful in the treatment of ulcerative colitis or Crohn's disease. Related methods and uses are also disclosed.
    Type: Application
    Filed: October 4, 2021
    Publication date: January 4, 2024
    Inventors: Ghaith Bakdash, Simon Harris, Dominika Klisko, Trevor Lawley, Seánín McCluskey, Thomas Mitchell, Anne Neville, Amy Popple, Oliver Rimington, Matthew Robinson, Michael Romanos, Adam Wilkinson
  • REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS
    Publication number: 20240000862
    Abstract: Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.
    Type: Application
    Filed: June 15, 2023
    Publication date: January 4, 2024
    Inventors: Sarkis K. Mazmanian, Timothy R. Sampson
  • Skin Probiotics
    Publication number: 20240000863
    Abstract: A topical, skin probiotic formulation comprises a living population of Corynebacterium glutamicum bacteria genetically-engineered to produce a skin-bioactive agent, and a nutrient source for the bacteria.
    Type: Application
    Filed: August 29, 2023
    Publication date: January 4, 2024
    Applicant: The Regents of the University of California
    Inventors: Amin Zargar, Jay D. Keasling
  • BACILLUS COAGULANS HAVING BLOOD GLUCOSE REDUCTION EFFICACY, AND APPLICATION THEREOF
    Publication number: 20240000864
    Abstract: Provided are a Bacillus coagulans strain VHProbi C08 having a blood glucose reduction efficacy and an application thereof in preparation of a hypoglycemic product. The accession number of the strain is CCTCCM 2019738. Further provided is a hypoglycemic product comprising the Bacillus coagulans VHProbi C08 and/or the fermentation product of Bacillus coagulans VHProbi C08. A carbon source used in the culture medium of the strain is any one or more of fructooligosaccharide, galactooligosaccharides, and inulin.
    Type: Application
    Filed: June 21, 2021
    Publication date: January 4, 2024
    Applicants: QINGDAO VLAND BIOTECH INC., QINGDAO VLAND BIOTECH GROUP CO., LTD.
    Inventors: Zhi DUAN, Hongchang CUI, Songjie WU, Jingyan ZHANG, Luxia ZHANG
  • BACILLUS SUBTILIS STRAIN WITH STRONG INHIBITION OF ENTEROPATHOGENIC AND FOODBORNE PATHOGENIC BACTERIA
    Publication number: 20240000865
    Abstract: The present invention generally relates to the field of microbiology, and more specifically to the Bacillus subtilis strain PS-216, which has been shown to have strong inhibitory activity against enteropathogenic and/or foodborne pathogenic bacteria, such as Campylobacter jejuni. More particularly, the present invention provides to new methods and uses of the Bacillus subtilis strain PS-216. The present invention also provides feed or food compositions and probiotic compositions comprising this strain.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 4, 2024
    Inventors: Ines Mandic Mulec, Katarina Simunovic, Polonca Stefanic, Andi Erega, Sonja Smole Mozina, Anja Klancnik, Qijing Zhang, Orhan Sahin
  • NOVEL STREPTOCOCCUS THERMOPHILUS STRAIN AND PROBIOTIC COMPOSITION AND USE THEREOF
    Publication number: 20240000866
    Abstract: The present disclosure provides a novel Streptococcus thermophilus strain, and the probiotic composition thereof and the use thereof for producing sialic acid and hyaluronic acid, anti-oxidation, anti-inflammatory, and alleviating dry eye syndrome. The novel Streptococcus thermophilus strain and/or metabolites thereof of the present disclosure can be used to prepare medicaments, food products, health food, and/or external products for anti-oxidation, anti-inflammation, and alleviating dry eye syndrome.
    Type: Application
    Filed: January 10, 2023
    Publication date: January 4, 2024
    Inventors: Meei-Yn Lin, Pin-Chao Huang, Pei-Cheng Lin, Tsung-Han Lu
  • SYNBIOTIC COMPOSITION
    Publication number: 20240000867
    Abstract: The present application relates to a synbiotic composition for use in the prevention, amelioration, treatment, or reductions of symptoms in an individual suffering from Inflammatory Bowel Disease (IBD) or from an infection with a respiratory virus or from long-term effects after an infection with a respiratory virus, wherein the synbiotic composition comprises at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and rice fibers.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 4, 2024
    Applicant: SYNBIOTICS AB
    Inventors: Ulla K SVENSSON, Catharina LAVEBRATT, Joëlle RÜEGG, Martin SCHALLING
  • Composition Containing Bifidobacterium Lactis and Human Milk Oligosaccharides and Application Thereof
    Publication number: 20240000868
    Abstract: The present disclosure provides a composition comprising Bifidobacterium lactis and human milk oligosaccharides (HMOs) and use thereof. The composition is capable of effectively enhancing resistance of an organism to Staphylococcus aureus infection, improving innate immunity of an organism, and/or anti-aging, and can be added to various health foods and healthcare foods.
    Type: Application
    Filed: November 16, 2021
    Publication date: January 4, 2024
    Inventors: Gisela Adrienne Weiss, Carolien Annika Van Loo-Bouwman, Gerrit Smit, Wendan Wang, Ignatius Man-Yau Szeto, Fangjie Gu, Biao Liu
  • SYNBIOTIC COMPOSITION
    Publication number: 20240000869
    Abstract: A synbiotic composition for use in the amelioration, treatment, reductions of symptoms of a neuropsychiatric disorder and/or the reduction of side effects of a pharmacological treatment of a neuropsychiatric disorder. The synbiotic composition includes at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and a rice fiber.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 4, 2024
    Applicant: SYNBIOTICS AB
    Inventors: Catharina LAVEBRATT, Joëlle RÜEGG, Martin SCHALLING
  • METHOD FOR ALLEVIATING OSTEOARTHRITIS
    Publication number: 20240000870
    Abstract: Disclosed herein is a method for alleviating osteoarthritis using a composition containing an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617.
    Type: Application
    Filed: May 16, 2023
    Publication date: January 4, 2024
    Inventors: Jin-Seng LIN, Chia-Chia LEE, Ting-Yu LEE, Han-Yin HSU, Jiu-Yao WANG
  • Lactobacillus gasseri capable of alleviating and treating hyperuricemia
    Publication number: 20240000871
    Abstract: The present disclosure discloses Lactobacillus gasseri capable of alleviating and treating hyperuricemia, which belongs to the technical field of microorganisms. The L. gasseri CCFM1133 of the present disclosure can reduce serum uric acid levels and the activity of serum and liver xanthine oxidase (XOD) of mice with hyperuricemia, and reduce the occurrence of hyperuricemia and gout; regulate glucose and serum triglyceride (TG) levels of patients with hyperuricemia, increase the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px); increase the expression of ileum ABCG2, promote the excretion of intestinal uric acid; and increase intestinal short-chain fatty acid levels to promote health. The L. gasseri CCFM1133 of the present disclosure can be used for preparing food, functional food or medicines, and has a wide application prospect.
    Type: Application
    Filed: June 15, 2023
    Publication date: January 4, 2024
    Inventors: Gang WANG, Caixin NI, Linlin WANG, Jianxin ZHAO, Hao ZHANG, Wei CHEN
  • NOVEL BACTERIOPHAGE THAT LYSES ACINETOBACTER GENUS BACTERIA HAVING RESISTANCE TO ANTIBIOTICS
    Publication number: 20240000872
    Abstract: The present invention relates to a novel bacteriophage that lyses Acinetobacter genus bacteria, in particular, Acinetobacter genus bacteria having resistance to antibiotics. The bacteriophage of the present invention can be used in various fields, such as antibiotic composition, feed additive composition, feed, disinfectant, cleaning agent, and a composition for prevention or treatment of an infectious disease caused by Acinetobacter genus bacteria.
    Type: Application
    Filed: July 13, 2023
    Publication date: January 4, 2024
    Inventors: Dong Eun YONG, Jong Soo JEON
  • REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES
    Publication number: 20240000873
    Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 4, 2024
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Kah-Whye Peng, Stephen James Russell, Camilo Ayala Breton
  • RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21
    Publication number: 20240000874
    Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
    Type: Application
    Filed: June 5, 2023
    Publication date: January 4, 2024
    Inventors: Philipp MUELLER, Klaus ERB, Patrik ERLMANN, Tobias Friederike NOLDEN, John Edward PARK, Guido WOLLMANN
  • COMPOSITIONS, SYSTEMS, & METHODS FOR IMPROVING HEALTH
    Publication number: 20240000875
    Abstract: Provided herein are product combinations, methods, kits, and compositions related to improving health and well-being in a subject. Methods of improving health and well-being may include ingesting a yerba mate supplement after waking, fasting for a fasting interval, and ingesting a fiber supplement before meal consumption.
    Type: Application
    Filed: June 29, 2023
    Publication date: January 4, 2024
    Inventor: Stewart Hughes
  • METHODS OF TREATING ENDOMETRIAL CANCER USING HEMP EXTRACT
    Publication number: 20240000876
    Abstract: A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.
    Type: Application
    Filed: September 15, 2023
    Publication date: January 4, 2024
    Inventors: Alexandra M. Capano, Pradeep Singh Tanwar, Alex Nance
  • GRANULATION OF TOPINAMBUR
    Publication number: 20240000877
    Abstract: A process for producing a granulate from a fermented topinambur syrup is disclosed. The product of the process is a free flowable granulate with a high content of carbohydrates such as inulin and fructooligosaccharides. Useful applications of this granulate are disclosed likewise.
    Type: Application
    Filed: October 6, 2020
    Publication date: January 4, 2024
    Applicant: Begapinol Holding GmbH
    Inventors: Ingo Saar, Marcus Heidenreich
  • METHODS FOR TREATMENT AND/OR PREVENTION OF VIRAL INFECTIONS
    Publication number: 20240000878
    Abstract: Methods for treating and/or preventing viral infections. In some implementations, a composition may be provided comprising a sugar alcohol, such as xylitol, xylose, and/or erythritol. The composition may further comprise an antihistamine and/or other active anti-viral compounds, such as grapefruit seed extract, preferably in a therapeutically effective amount and/or concentration for treating a viral infection in a human having such a viral infection.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 4, 2024
    Inventor: Nathan Jones
  • HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY
    Publication number: 20240000879
    Abstract: Herbal compositions in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The herbal composition/carrier combinations can create administration benefits.
    Type: Application
    Filed: September 13, 2023
    Publication date: January 4, 2024
    Applicant: Spoke Sciences, Inc.
    Inventors: Andrea Leone-Bay, Gregory Wesner
  • A PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING LUNG INJURY, A PREPARATION METHOD THEREFOR AND A USE THEREOF
    Publication number: 20240000880
    Abstract: The disclosure relates to a pharmaceutical composition having the efficacy of preventing and treating lung injury, a preparation method therefor and a use thereof. The composition comprises a grape powder with a content of 1-25% (w/w), a grape seed extract with a content of 0.5-15% (w/w) and a pharmaceutically acceptable carrier. The composition of the disclosure has the efficacy of preventing and treating lung injury, oxidative injury, inhibiting pulmonary fibrosis, regulating lipid metabolism, and the like.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 4, 2024
    Inventors: Hongtao JIN, Peicheng ZHANG, Jinlan ZHANG, Jiandong JIANG, Ping ZHANG, Yangyang LI
  • TOPICAL TREATMENT FOR ANIMALS
    Publication number: 20240000881
    Abstract: A topical formulation and method of using the formulation on animals including dogs is disclosed. The formulation is used to facilitate the healing of cuts, scrapes, abrasions, and other conditions often experienced by animals. A main ingredient of the formulation is sulfur in a high concentration.
    Type: Application
    Filed: May 18, 2023
    Publication date: January 4, 2024
    Inventor: Crystal-Ray Kanoelani Naone
  • COMPOSITIONS AND METHODS FOR BODY CONTOURING AND SURGICAL PROCEDURES
    Publication number: 20240000882
    Abstract: Disclosed herein are topical compositions and methods of use for improving or ameliorating effects associated with body contouring or surgical procedures. Compositions as described herein comprise one or more peptides.
    Type: Application
    Filed: July 18, 2023
    Publication date: January 4, 2024
    Applicant: ALASTIN SKINCARE, INC.
    Inventors: Alan David WIDGEROW, John A. GARRUTO
  • METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS
    Publication number: 20240000883
    Abstract: The invention described relates to the newly discovered ability of tumor internalizing arginylglycylaspartic acid (iRGD) peptides to alter the immune cell landscape in pancreatic ductal adenocarcinoma (PDAC) and other cancers. The iRGD peptides sensitize the cancer to immune checkpoint inhibitors, for example anti-PD-L1, anti-PD-L1, anti-PD-1, and anti-CTLA4 monoclonal antibodies to specifically deplete Tregs within the tumor, resulting in expansion of intratumoral CD8+ T cells (effector cells). This provides methods of treating cancers such as PDAC, preferably in synergistic combination with chemotherapy and immunotherapy, which leads to reduced tumor burden and prolonged survival.
    Type: Application
    Filed: December 1, 2021
    Publication date: January 4, 2024
    Inventors: Kazuki SUGAHARA, Andrew M. LOWY
  • AQUEOUS SOLUTION
    Publication number: 20240000884
    Abstract: The present invention relates to an aqueous solution comprising glycopeptide antibiotics, selected from the group consisting of vancomycin, telavancin, oritavancin, teicoplanin, dalbavancin and mixtures thereof, especially vancomycin, and N-acetylated D-cysteine (D-aCys), the solution having a pH of from about 4.0 to 7.0 and preferably being present in a suitable container with air as headspace. The invention relates further to the use of such an aqueous solution as a medicament, especially for use in the treatment of bacterial infections, and a method for stabilizing glycopeptide antibiotics, especially vancomycin.
    Type: Application
    Filed: December 16, 2021
    Publication date: January 4, 2024
    Inventors: Maria-Lena ACHLEITNER, Michael HESSENBERGER, Heinz SCHNAIT
  • COMPOSITIONS AND METHODS FOR TARGETING THE INTERACTION OF HOST MYO5B+D AND CORONAVIRUS M PROTEINS
    Publication number: 20240000885
    Abstract: Disclosed herein is a method for treating or preventing a coronavirus infection in a subject that involves administering to the subject an effective amount of a composition comprising an agent that disrupts the binding of coronavirus membrane glycoprotein (M protein) and Myosin Vb protein (MYO5B). Also disclosed herein is a method for identifying an agent for treating or preventing a coronavirus infection that involves providing a system comprising coronavirus membrane glycoprotein (M protein) and human Myosin Vb protein (MYO5B) with conditions suitable for binding of the M protein and MYO5B; contacting the system with a candidate agent; and assaying the system for binding of M protein and MYO5B.
    Type: Application
    Filed: November 3, 2021
    Publication date: January 4, 2024
    Inventors: Frédéric TANGY, Pierre-Olivier VIDALAIN, James R. GOLDENRING, Joseph T. Roland, Lynne A. LAPIERRE, Elizabeth MANNING, Cornelis Alexander Maria DE HAAN
  • Compositions and Methods for Treating Spinal Muscular Atrophy
    Publication number: 20240000886
    Abstract: The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered in the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated.
    Type: Application
    Filed: April 21, 2023
    Publication date: January 4, 2024
    Applicant: Genzyme Corporation
    Inventors: Marco A. Passini, Lamya S. Shihabuddin, Catherine R. O'Riordan, Seng H. Cheng
  • LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF
    Publication number: 20240000887
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Application
    Filed: August 4, 2023
    Publication date: January 4, 2024
    Applicant: ABIONYX PHARMA SA
    Inventors: Jean-Louis DASSEUX, Rose ACKERMANN, Daniela Carmen ONICIU
  • GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF
    Publication number: 20240000888
    Abstract: The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-?2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity.
    Type: Application
    Filed: August 14, 2023
    Publication date: January 4, 2024
    Inventors: Michael J. Tisdale, Steven T. Russell
  • METHOD FOR TREATING OR PREVENTING IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)
    Publication number: 20240000889
    Abstract: A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-C5 agent) and Eylea® (or another VEGF antagonist).
    Type: Application
    Filed: February 8, 2023
    Publication date: January 4, 2024
    Applicant: IVERIC bio, Inc.
    Inventor: Kourous Rezaei
  • NEURAL REGENERATION WITH SYNTHETIC PROTEIN ADMINISTRATION
    Publication number: 20240000890
    Abstract: A method for neural regeneration is provided at specific situses that include the inner ear and retina, where Ganglion cells respond to the method through at least stimulation of such cells. As a result, the method provides for reversing clinical conditions associated with the nerve degradation or disease. Specific clinical conditions reversed at least in part through nerve regeneration include hearing loss, tinnitus, and a host of neurotrophic retinopathies, diabetes, Norrie disease, and others. Nerve regeneration is accomplished with a protein that is a truncated synthetic polypeptide related to native norrin protein. Truncated norrin proteins have a longer half-life in the situs than native norrin proteins. A version of the truncated norrin protein lacks a cleavage site for a subject protease enzyme that cleaves native norrin proteins and thereby shortens the useful life of the therapeutic protein.
    Type: Application
    Filed: January 11, 2021
    Publication date: January 4, 2024
    Applicant: Retinal Solutions, LLC
    Inventors: Kimberly Drenser, Michael T. Trese, Antonio Capone
  • GROWTH AND DIFFERENTIATION FACTOR 15 FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY THERAPY
    Publication number: 20240000891
    Abstract: An effective dose of Growth Differentiation Factor 15 (GDF15) is used for prevention or treatment of proliferative vitreoretinopathy. Specifically, the disclosure provides methods and compositions for treatment of proliferative vitreoretinopathy (PVR), which is based on preventing or reducing proliferation, cell migration, or epithelial-mesenchymal transition (EMT) of epithelial cells involved in PVR.
    Type: Application
    Filed: December 7, 2021
    Publication date: January 4, 2024
    Inventors: Jeffrey Louis Goldberg, Kun-Che Chang
  • Agents and Methods for Increasing Liver Immune Response
    Publication number: 20240000892
    Abstract: An agent that increases the number ofKupffer cells in a subject, or a nucleotide sequence encoding therefor, for use in a method of therapy by increasing liver immune response.
    Type: Application
    Filed: November 26, 2021
    Publication date: January 4, 2024
    Inventors: Luca Guidotti, Matteo Iannacone
  • MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSIS
    Publication number: 20240000893
    Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.
    Type: Application
    Filed: June 29, 2023
    Publication date: January 4, 2024
    Applicants: UCB BIOPHARMA SRL, FIVE PRIME THERAPEUTICS, INC.
    Inventors: Timothy Scott JOHNSON, Breda TWOMEY, Janine POWERS, Danielle E. KELLAR
  • TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39)
    Publication number: 20240000894
    Abstract: Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.
    Type: Application
    Filed: February 22, 2023
    Publication date: January 4, 2024
    Inventors: Tracey L. MCLAUGHLIN, Colleen M. CRAIG
  • Treatment Of Females Having BRCA1/2 Mutations With Human Chorionic Gonadotropin To Reduce The Risk Of Developing Breast Cancer
    Publication number: 20240000895
    Abstract: Methods of treating nulligravid females having a high risk of developing breast cancer and without exposure to a contraceptive by administering human chorionic gonadotropin (hCG), methods of monitoring the treatment efficacy of a subject having breast cancer or having a high risk of developing breast cancer, and methods of determining whether a subject is at risk of developing breast cancer are provided herein.
    Type: Application
    Filed: December 6, 2021
    Publication date: January 4, 2024
    Inventors: Jose Russo, Herman Depypere, Yanrong Su, Nhi Dang, Jaak Janssens
  • ELEVATED INTRACRANIAL PRESSURE TREATMENT
    Publication number: 20240000896
    Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 4, 2024
    Inventor: Alex SINCLAIR
  • INJECTABLE BIODEGRADABLE POLYMERIC COMPLEX FOR GLUCOSE-RESPONSIVE INSULIN DELIVERY
    Publication number: 20240000897
    Abstract: A glucose-responsive therapeutic material demonstrates consistent and slow basal insulin release under a normoglycemic condition and accelerated insulin release in response to hyperglycemia. The therapeutic material uses a poly-L-lysine-derived polymer (PLL) modified with 4-carboxy-3-fluorophenylboronic acid (FPBA) that forms a polymer-insulin complex for glucose-stimulated insulin delivery. The release profile of the therapeutic material may be adjusted or tuned by altering the ratio of modified polymer (PLL-FPBA) to insulin in the therapeutic material, FPBA-modification degree of polymer, and altering the molecular weight of the polymer. The therapeutic material may be delivered to a mammalian subject using a delivery device (e.g., subcutaneous injection).
    Type: Application
    Filed: November 30, 2021
    Publication date: January 4, 2024
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Zhen Gu, Jinqiang Wang
  • IN VIVO SYNTHESIS OF ELASTIC FIBER
    Publication number: 20240000898
    Abstract: Disclosed herein are methods of restoring elasticity in tissue using tropoelastin containing compositions.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 4, 2024
    Inventors: Suzanne Marie MITHIEUX, Anthony Steven WEISS
  • THERAPEUTIC USEFUL AGAINST ANTIMICROBIAL RESISTANT AGENTS
    Publication number: 20240000899
    Abstract: A pharmaceutically acceptable therapeutic inhalation fluid that is composed of a fluid carrier and a pharmaceutically acceptable acid formulation present in the fluid carrier in an amount sufficient to provide a solution pH between 1.5 and 2.5, the pharmaceutically acceptable acid formulation having anti-bacterial, and/or anti-viral, and/or anti-fungal activity and at least one antimicrobial peptide.
    Type: Application
    Filed: May 23, 2023
    Publication date: January 4, 2024
    Inventors: Paul Bundschuh, Lawrence Carlson, Shawn Dolan
  • COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH AN IMPRINTING DEFECT
    Publication number: 20240000900
    Abstract: The invention provides methods for activating a repressed allele within an imprinting control region, thereby treating an imprinting associated disorder.
    Type: Application
    Filed: June 26, 2023
    Publication date: January 4, 2024
    Applicant: The Children's Medical Center Corporation
    Inventors: Yi ZHANG, Azusa INOUE